中基長壽科學(00767.HK):中驪與北京三有利就牙髓幹細胞項目在海南開展技術應用推廣
中基長壽科學(00767.HK)公佈,公司之間接非全資附屬中驪與北京三有利訂立技術推廣協議,北京三有利和中驪將開展技術推廣合作。
雙方會就異體人牙髓間充質幹細胞注射液治療牙周炎項目,在海南省瓊海市博鰲鎮博鰲樂城國際醫療旅遊先行區經批準後開展技術應用推廣服務相關事宜。
牙髓幹細胞項目在獲得先行區技術合規批準和收費許可後,北京三有利將向合作醫療機構、合作代理商業機構推薦中驪作爲牙髓幹細胞項目技術應用推廣服務商、在全球範圍內按照國家法律法規要求開展該專案技術轉化應用的推廣服務,協同北京三有利及其合作方共同開展牙髓幹細胞項目的技術推廣和商業化落地,包括但不限於專案宣傳推廣及市場化營運拓展。
北京三有利關注於幹細胞與生物醫藥研發,核心業務包括細胞治療藥物開發及GMP細胞製備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.